SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (CYTK) today announced that additional results from a new analysis of REDWOOD-HCM (Randomized Eevaluation of Dto dare Owith CK-274 in Oconstructive Oexit Dis sick in HCM) regarding the effect of treatment with to affirm on measures of cardiac structure and function will be presented in a poster presentation at the American Society of Echocardiography (ASE) 33rd Annual Scientific Sessions, taking place in person in Seattle and online from June 10, 2022 through June 13, 2022. A recording of the presentation will be available upon request to registered attendees beginning July 11, 2022 at 10:00 a.m. ET.
Title: Early Cardiac Structural and Functional Reverse Remodeling in Obstructive Hypertrophic Cardiomyopathy After 10 Weeks of Aficamten Therapy: REDWOOD-HCM Analyzes
Presenter: Theodore Abraham, MD, FACC, FASE, Professor of Medicine, Department of Cardiology, University of California, San Francisco; Co-Director, UCSF HCM Center of Excellence; Director, UCSF Adult Cardiac Echocardiography Laboratory
Date: June 11, 2022
Topic: Echocardiography in myocardial diseases (HCM, amyloidosis, sarcoidosis, Chagas)
Session title: President’s Circle Poster Session
Session time: 4:00-6:00 PM PT
Location: Expo Echo
Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class muscle activators and cutting-edge muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company develops small molecule drug candidates specifically designed to impact muscle function and contractility. Cytokinetics prepares for potential commercialization of mecarbil omecamtiv, its heart muscle enhancer, following positive results from GALACTIC-HF, a large international Phase 3 clinical trial in patients with heart failure. Cytokinetics also develops to affirma next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the phase 3 clinical trial of to affirm in patients with symptomatic hypertrophic obstructive cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics also develops relative, an investigational fast skeletal muscle troponin activator, which is currently undergoing COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its 20+ year history of pioneering innovation in muscle biology and related pharmacology focused on muscle dysfunction diseases and muscle weakness conditions.
For more information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
This press release contains forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intention or obligation to update these forward-looking statements and claims the protection of the safe harbor of law for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to one of our other clinical trials, statements relating to the potential benefits of mecarbil omecamtiv, to affirm, or one of our other drug candidates. the research and development activities of Cytokinetics; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of other Cytokinetics drug candidates. These statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in development, testing, regulatory approvals for the initiation of testing, development or sale of products or the manufacture or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have undesirable side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may not be able to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics drug candidates obsolete; and competing products or alternative therapies may be developed by others for the treatment of indications that Cytokinetics’ drug candidates and potential drug candidates may target. For more information regarding these and other risks associated with Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shape logo are registered trademarks of Cytokinetics in the United States and certain other countries.
Senior Vice President, Corporate Communications, Investor Relations